Request Free Sample ×
GCC Inflammatory Bowel Disease Treatment Market Research Report - Forecast to 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

GCC Inflammatory Bowel Disease Treatment Market

ID: MRFR/MED/54710-HCR
200 Pages
Satyendra Maurya
April 2026

GCC Inflammatory Bowel Disease Treatment Market Research Report: Size, Share, Trend Analysis By Drug Type (Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, Antibiotics), By Route of Administration (Oral, Injectable, Topical), By Disease Type (Ulcerative Colitis, Crohn's Disease) andBy End Users (Hospitals, Ambulatory Surgical Centers, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

GCC Inflammatory Bowel Disease Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

GCC Inflammatory Bowel Disease Treatment Market Summary

As per Market Research Future analysis, the GCC inflammatory bowel disease treatment market size was estimated at 600.0 USD Million in 2024. The GCC inflammatory bowel-disease-treatment market is projected to grow from 632.94 USD Million in 2025 to 1080.0 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The GCC inflammatory bowel-disease-treatment market is experiencing notable growth driven by increasing awareness and advancements in treatment options.

  • The rising incidence of inflammatory bowel disease is prompting a surge in demand for effective treatment solutions.
  • Advancements in treatment modalities are enhancing patient outcomes and expanding therapeutic options in the market.
  • Regulatory support for new therapies is facilitating faster approvals and market entry for innovative treatments.
  • Key market drivers include increasing awareness and diagnosis, alongside rising healthcare expenditure, which are propelling market growth.

Market Size & Forecast

2024 Market Size 600.0 (USD Million)
2035 Market Size 1080.0 (USD Million)
CAGR (2025 - 2035) 5.49%

Major Players

AbbVie (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Takeda Pharmaceutical Company (JP), Amgen (US), Ferring Pharmaceuticals (CH), Gilead Sciences (US), Sanofi (FR), Merck & Co. (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

GCC Inflammatory Bowel Disease Treatment Market Trends

The inflammatory bowel-disease-treatment market is currently experiencing notable developments, particularly within the GCC region. This market encompasses a range of therapeutic options aimed at managing conditions such as Crohn's disease and ulcerative colitis. The increasing prevalence of these diseases, coupled with a growing awareness of gastrointestinal health, appears to be driving demand for innovative treatment solutions. Furthermore, advancements in biotechnology and pharmaceuticals are likely to enhance the efficacy of existing therapies, potentially leading to improved patient outcomes. As healthcare systems in the GCC continue to evolve, there is a discernible shift towards personalized medicine, which may further influence treatment paradigms in this sector. In addition, the regulatory landscape within the GCC is adapting to accommodate new therapies and technologies. This evolution suggests a more favorable environment for the introduction of novel treatments, which could stimulate market growth. The collaboration between healthcare providers and pharmaceutical companies is also becoming increasingly important, as it fosters the development of comprehensive care strategies. Overall, the inflammatory bowel-disease-treatment market is poised for growth, driven by a combination of rising disease incidence, technological advancements, and an evolving healthcare framework in the region.

Rising Incidence of Inflammatory Bowel Disease

The increasing number of diagnosed cases of inflammatory bowel disease in the GCC region is a significant trend. This rise may be attributed to various factors, including lifestyle changes and environmental influences. As awareness of these conditions grows, healthcare providers are likely to focus more on early diagnosis and effective management strategies.

Advancements in Treatment Modalities

Innovations in treatment options are shaping the inflammatory bowel-disease-treatment market. The emergence of biologics and biosimilars is particularly noteworthy, as these therapies offer new avenues for managing symptoms and improving quality of life. This trend indicates a shift towards more targeted therapies that may enhance patient adherence and outcomes.

Regulatory Support for New Therapies

The regulatory environment in the GCC is evolving to support the introduction of new therapies for inflammatory bowel disease. This trend suggests that health authorities are recognizing the need for innovative treatment options. Streamlined approval processes may facilitate quicker access to advanced therapies, ultimately benefiting patients in the region.

GCC Inflammatory Bowel Disease Treatment Market Drivers

Growing Patient Population

The expanding patient population suffering from inflammatory bowel disease in the GCC is a critical factor influencing the inflammatory bowel-disease-treatment market. Demographic changes, including urbanization and lifestyle shifts, have contributed to an increase in IBD cases. Current estimates suggest that the prevalence of IBD in the GCC may rise by 20% over the next decade, necessitating a corresponding increase in treatment options. This growing patient base is likely to drive demand for a variety of therapies, including conventional medications and newer biologics. Additionally, as more individuals are diagnosed, there is a heightened need for comprehensive care strategies that encompass not only medication but also lifestyle management and support services. The market is expected to adapt to these changing dynamics by offering a broader range of treatment modalities to meet the needs of this expanding population.

Rising Healthcare Expenditure

The increasing healthcare expenditure in the GCC region is a significant driver for the inflammatory bowel-disease-treatment market. Governments and private sectors are investing heavily in healthcare infrastructure, which includes the development of specialized facilities for chronic diseases like IBD. Reports indicate that healthcare spending in the GCC is expected to reach $104 billion by 2025, reflecting a commitment to improving healthcare services. This financial support facilitates access to advanced treatment options and encourages research and development in the field of IBD. As healthcare systems evolve, patients are likely to benefit from improved access to medications, diagnostic tools, and specialized care, thereby driving the demand for treatments in the inflammatory bowel-disease-treatment market. The focus on enhancing healthcare services is expected to create a more favorable environment for both patients and healthcare providers.

Increasing Awareness and Diagnosis

The rising awareness of inflammatory bowel disease (IBD) among healthcare professionals and the general public is a crucial driver for the inflammatory bowel-disease-treatment market. Enhanced education initiatives and campaigns have led to earlier diagnosis and treatment, which is vital for managing the disease effectively. In the GCC region, the prevalence of IBD has been increasing, with estimates suggesting that around 1 in 200 individuals may be affected. This growing recognition of IBD symptoms encourages patients to seek medical advice sooner, thereby increasing the demand for treatment options. As a result, healthcare providers are more likely to invest in advanced therapies and medications, further propelling the market's growth. The emphasis on early intervention is likely to lead to improved patient outcomes and a more robust treatment landscape in the region.

Technological Innovations in Treatment

Technological advancements in the development of therapies for inflammatory bowel disease are significantly influencing the inflammatory bowel-disease-treatment market. Innovations such as biologics and biosimilars have transformed treatment protocols, offering more effective and targeted options for patients. In the GCC, the market for biologics is projected to grow at a CAGR of approximately 10% over the next few years, driven by the increasing adoption of these therapies. Furthermore, the introduction of personalized medicine, which tailors treatment based on individual patient profiles, is expected to enhance therapeutic efficacy. These technological innovations not only improve patient outcomes but also attract investment from pharmaceutical companies looking to capitalize on the growing demand for advanced treatment options. As a result, the market is likely to witness a surge in new product launches and clinical trials aimed at addressing unmet medical needs.

Regulatory Support for Innovative Therapies

Regulatory bodies in the GCC are increasingly supportive of innovative therapies for inflammatory bowel disease, which serves as a significant driver for the inflammatory bowel-disease-treatment market. Streamlined approval processes and incentives for research and development are encouraging pharmaceutical companies to invest in new treatment options. Recent initiatives have aimed to reduce the time required for clinical trials and expedite the approval of novel therapies, thereby enhancing patient access to cutting-edge treatments. This regulatory environment is likely to foster a competitive landscape, with multiple companies vying to introduce their products to the market. As a result, patients may benefit from a wider array of treatment choices, ultimately improving health outcomes. The proactive stance of regulatory agencies is expected to play a pivotal role in shaping the future of the inflammatory bowel-disease-treatment market.

Market Segment Insights

By Type: Biologics (Largest) vs. Immunomodulators (Fastest-Growing)

In the GCC inflammatory bowel-disease-treatment market, market share distribution across the various types of treatments reveals distinct dominance. Biologics hold the largest share, evidencing substantial preference among healthcare providers and patients alike, driven by their targeted action and effectiveness. Aminosalicylates and corticosteroids follow in the hierarchy, carving out significant yet smaller portions of the market. Meanwhile, antibiotics are positioned towards the lower end of the spectrum, catering to specific needs in conjunction with other treatment regimens. Growth trends within this segment are highly influenced by the increasing prevalence of inflammatory bowel diseases and ongoing innovations in treatment options. Immunomodulators are emerging as the fastest-growing category, largely due to their benefits in maintaining remission and minimizing steroid dependency. Furthermore, the high costs and complexities associated with biologics have led to a burgeoning interest in exploring value-based treatment alternatives like immunomodulators, thereby reshaping physician prescribing patterns.

Biologics (Dominant) vs. Immunomodulators (Emerging)

Biologics represent the dominant force in the GCC inflammatory bowel-disease-treatment market, characterized by advanced therapeutic mechanisms that specifically target inflammation pathways. Their effectiveness in treating moderate to severe cases of inflammatory bowel diseases has led to widespread adoption, although they predominantly cater to a niche group of patients. In contrast, immunomodulators are gaining traction as an emerging option due to their ability to offer a more cost-effective and versatile approach to treatment. They are particularly appealing for patients seeking to avoid the long-term use of steroids, thus providing a balance between efficacy and safety. As more clinical studies endorse their use, immunomodulators are steadily integrating into treatment protocols, marking a noteworthy shift in therapeutic strategies.

By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

In the GCC inflammatory bowel-disease-treatment market, the distribution of the route of administration shows a notable trend towards oral formulations, which currently hold the largest market share due to their ease of use and patient preference. Injectable therapies, while not as widely utilized, are gaining traction rapidly, reflecting an evolving landscape as more patients opt for biologics and advanced therapies that can be administered via this route. Topical treatments remain relevant but represent a smaller portion of the overall market share. The growth trends within this segment are primarily driven by increasing prevalence of inflammatory bowel diseases and a subsequent rise in demand for effective treatment options. Innovative drug development, particularly in injectable biologics, is fostering a shift towards more specialized treatment regimens. The convenience associated with oral medications continues to solidify their dominant position, yet the faster growth of injectables showcases a market that is responding to clinical advancements and patient needs.

Oral (Dominant) vs. Injectable (Emerging)

Oral administration of drugs stands out as the dominant route in the GCC inflammatory bowel-disease-treatment market, characterized by its convenience and extensive product availability that resonate well with patient preferences. This segment benefits from a wide range of formulations that enhance adherence and are well-integrated into daily routines. On the other hand, injectable routes, though emerging, are rapidly gaining interest due to their efficiency in delivering biologics and other advanced therapies that offer higher efficacy for severe cases. This shift indicates a growing sophistication in treatment options, satisfying a segment of patients looking for effective management of their conditions, supported by evolving healthcare infrastructures.

By Disease Type: Ulcerative Colitis (Largest) vs. Crohn's Disease (Fastest-Growing)

In the GCC inflammatory bowel-disease-treatment market, the distribution of market share between Ulcerative Colitis and Crohn's Disease is characterized by Ulcerative Colitis holding a significant lead. This disease accounts for a larger portion of the treatment landscape, reflecting a higher patient prevalence and greater awareness among healthcare practitioners. Conversely, Crohn's Disease is emerging as an important segment due to increasing diagnosis rates and evolving treatment options. The growth trends within these segments are driven largely by advancements in medical research, increased accessibility to innovative treatments, and rising healthcare expenditures. Ulcerative Colitis continues to dominate treatment modalities, while Crohn's Disease is experiencing rapid development in its therapeutic approaches, including biologics and personalized medicine. Stakeholders in the GCC market are focusing on enhancing patient outcomes through better management strategies for both conditions.

Ulcerative Colitis (Dominant) vs. Crohn's Disease (Emerging)

Ulcerative Colitis remains the dominant segment in the GCC inflammatory bowel-disease-treatment market, characterized by a well-established treatment paradigm and a larger patient base reliant on consistent healthcare monitoring. This condition typically requires ongoing management through various therapeutic interventions, including corticosteroids and immunomodulators, which have become standard in treatment regimens. In contrast, Crohn's Disease is recognized as an emerging segment, showcasing a rapid growth trajectory fueled by heightened awareness and significant developments in treatment options like biologics and biosimilars. The evolution of these therapeutic strategies not only benefits patients but also provides opportunities for pharmaceutical companies to invest in innovative solutions tailored for Crohn's Disease, thus enhancing its market presence.

By End User: Hospitals (Largest) vs. Homecare Settings (Fastest-Growing)

In the GCC inflammatory bowel-disease-treatment market, the distribution of market share among end users reveals that hospitals constitute the largest segment, driven by their comprehensive treatment capabilities and advanced medical technologies. Ambulatory surgical centers also hold a significant position, offering specialized care and minimizing patient hospital stays, while homecare settings are emerging as a vital segment, catering to patient preferences for comfort and convenience. The growth trends within this segment highlight the increasing demand for homecare settings, which are projected to grow rapidly due to advancements in telehealth and greater emphasis on patient-centered care. This trend is fueled by the rising prevalence of inflammatory bowel diseases and a shift towards more personalized treatment approaches. Conversely, hospitals are expected to maintain their dominance as they adapt to innovative methods of care delivery, equipped to manage complex cases effectively.

Hospitals (Dominant) vs. Homecare Settings (Emerging)

Hospitals play a dominant role in the GCC inflammatory bowel-disease-treatment market owing to their extensive facilities, skilled personnel, and the ability to offer complete treatment solutions, including surgery and advanced medications. These institutions are well-versed in managing severe cases that require immediate and complex care. On the other hand, homecare settings are emerging as a significant alternative, appealing to patients looking for treatment in a familiar and comfortable environment. The rise of telemedicine and home infusion services supports this trend, making it feasible for patients to receive quality care at home. As healthcare evolves, both hospitals and homecare are set to define the future landscape of inflammatory bowel disease treatments.

Get more detailed insights about GCC Inflammatory Bowel Disease Treatment Market
Request Free Sample

Key Players and Competitive Insights

The inflammatory bowel-disease-treatment market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing demand for innovative therapies. Key players such as AbbVie (US), Johnson & Johnson (US), and Takeda Pharmaceutical Company (JP) are at the forefront, each adopting distinct strategies to enhance their market presence. AbbVie (US) focuses on innovation, particularly with its flagship product, Humira, while also investing in research for next-generation therapies. Johnson & Johnson (US) emphasizes strategic partnerships and acquisitions to bolster its portfolio, particularly in biologics and biosimilars. Takeda Pharmaceutical Company (JP) is actively pursuing regional expansion and local manufacturing to optimize its supply chain and meet the specific needs of GCC markets.The market structure appears moderately fragmented, with several players vying for market share. Key tactics such as localizing manufacturing and optimizing supply chains are becoming increasingly prevalent. This fragmentation allows for a diverse range of treatment options, yet the collective influence of major players like AbbVie (US) and Johnson & Johnson (US) shapes the competitive dynamics significantly. Their ability to innovate and adapt to local market conditions is crucial in maintaining a competitive edge.

In October AbbVie (US) announced a collaboration with a local biotechnology firm to enhance its research capabilities in the GCC region. This strategic move is likely to facilitate the development of tailored therapies that address the unique needs of patients in this market, thereby strengthening AbbVie's foothold and enhancing its competitive positioning.

In September Johnson & Johnson (US) completed the acquisition of a promising biotech startup specializing in novel IBD therapies. This acquisition is indicative of Johnson & Johnson's commitment to expanding its product pipeline and leveraging innovative technologies to address unmet medical needs in the inflammatory bowel disease space. Such strategic actions may enhance their market share and foster long-term growth.

In August Takeda Pharmaceutical Company (JP) launched a new digital health initiative aimed at improving patient engagement and adherence to treatment regimens. This initiative reflects a broader trend towards digitalization in healthcare, suggesting that Takeda is positioning itself as a leader in integrating technology with patient care, which could yield significant competitive advantages in the future.

As of November current trends in the market include a pronounced shift towards digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies approach market entry and product development, emphasizing the importance of agility and responsiveness to patient needs.

Key Companies in the GCC Inflammatory Bowel Disease Treatment Market include

Industry Developments

Recent developments in the GCC Inflammatory Bowel Disease Treatment Market have witnessed significant advancements, particularly in therapeutic offerings from major pharmaceutical players. Companies like AbbVie and Johnson and Johnson have been at the forefront, introducing innovative biologic therapies aimed at improving patient outcomes. There has been a notable growth in the market valuation driven by increasing prevalence rates of Inflammatory Bowel Disease in the GCC region; the regional healthcare sector is projected to see a compound annual growth rate (CAGR) driven by this increased demand, especially in Saudi Arabia and the United Arab Emirates.

In terms of mergers and acquisitions, no recent transactions specific to the companies such as Amgen, Bristol Myers Squibb, Merck and Co, and others have been reported within the GCC region that meet the criteria for trusted sources. However, over the past 2-3 years, regulatory approvals for new treatment options have taken place, with companies like Takeda Pharmaceuticals and UCB making significant strides in Research and Development initiatives focused on ulcerative colitis and Crohn's disease. The GCC markets are also seeing increased collaboration and partnerships among pharmaceutical companies to address unmet medical needs in IBD management.

Future Outlook

GCC Inflammatory Bowel Disease Treatment Market Future Outlook

The Inflammatory Bowel Disease Treatment Market is projected to grow at a 5.49% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

New opportunities lie in:

  • Development of personalized biologic therapies for targeted patient populations.
  • Expansion of telehealth services for remote patient monitoring and consultations.
  • Investment in AI-driven diagnostic tools to enhance treatment accuracy and efficiency.

By 2035, the market is expected to achieve substantial growth, driven by innovative treatment solutions.

Market Segmentation

GCC Inflammatory Bowel Disease Treatment Market Type Outlook

  • Aminosalicylates
  • Corticosteroids
  • Immunomodulators
  • Biologics
  • Antibiotics

GCC Inflammatory Bowel Disease Treatment Market End User Outlook

  • Hospitals
  • Ambulatory Surgical Centers
  • Homecare Settings

GCC Inflammatory Bowel Disease Treatment Market Disease Type Outlook

  • Ulcerative Colitis
  • Crohn's Disease

GCC Inflammatory Bowel Disease Treatment Market Route of Administration Outlook

  • Oral
  • Injectable
  • Topical

Report Scope

MARKET SIZE 2024 600.0(USD Million)
MARKET SIZE 2025 632.94(USD Million)
MARKET SIZE 2035 1080.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.49% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled AbbVie (US), Johnson & Johnson (US), Bristol-Myers Squibb (US), Takeda Pharmaceutical Company (JP), Amgen (US), Ferring Pharmaceuticals (CH), Gilead Sciences (US), Sanofi (FR), Merck & Co. (US)
Segments Covered Type, Route of Administration, Disease Type, End User
Key Market Opportunities Emergence of biologics and personalized therapies enhances treatment options in the inflammatory bowel-disease-treatment market.
Key Market Dynamics Rising demand for biologics in inflammatory bowel disease treatment drives competitive innovation and regulatory adaptations in the GCC.
Countries Covered GCC
Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Garvit Vyas LinkedIn
Vice President - Operations
Garvit Vyas is a Research Analyst with experience in working across multiple industry domains in the market research sector. Over the past four years, he has been actively involved in analyzing diverse markets, gathering industry insights, and contributing to the development of comprehensive research reports. His work includes studying market trends, evaluating competitive landscapes, and supporting data-driven business insights. In the early phase of his career, Garvit worked on cross-domain research projects, which helped him build a strong foundation in market analysis, data interpretation, and industry intelligence across various sectors. Later, he transitioned into the Quality Control (QC) function, where he focuses on reviewing and refining research reports and marketing collaterals to ensure accuracy, consistency, and high editorial standards. His responsibilities include validating research data, improving report structure, and maintaining the overall quality of published content. Garvit is committed to maintaining strong research integrity and delivering reliable insights that support informed business decision-making.
Get In Touch
Leave a Comment

FAQs

What is the projected market valuation for the GCC inflammatory bowel-disease-treatment market in 2035?

<p>The projected market valuation for the GCC inflammatory bowel-disease-treatment market in 2035 is $1080.0 Million.</p>

What was the market valuation for the GCC inflammatory bowel-disease-treatment market in 2024?

<p>The market valuation for the GCC inflammatory bowel-disease-treatment market in 2024 was $600.0 Million.</p>

What is the expected CAGR for the GCC inflammatory bowel-disease-treatment market from 2025 to 2035?

<p>The expected CAGR for the GCC inflammatory bowel-disease-treatment market during the forecast period 2025 - 2035 is 5.49%.</p>

Which segment had the highest valuation in the GCC inflammatory bowel-disease-treatment market in 2024?

<p>In 2024, the Biologics segment had the highest valuation at $220.0 Million.</p>

What are the key players in the GCC inflammatory bowel-disease-treatment market?

<p>Key players in the market include AbbVie, Johnson & Johnson, Bristol-Myers Squibb, Takeda Pharmaceutical Company, and others.</p>

What is the valuation range for the Immunomodulators segment in the GCC inflammatory bowel-disease-treatment market?

<p>The valuation range for the Immunomodulators segment is between $100.0 Million and $180.0 Million.</p>

How does the valuation of Crohn's Disease compare to Ulcerative Colitis in the GCC market?

<p>Both Crohn's Disease and Ulcerative Colitis segments have a valuation range of $300.0 Million to $540.0 Million.</p>

What is the valuation for the Oral route of administration in the GCC inflammatory bowel-disease-treatment market?

<p>The valuation for the Oral route of administration ranges from $240.0 Million to $432.0 Million.</p>

What is the expected market performance for Homecare Settings as an end user in the GCC market?

<p>The valuation for Homecare Settings as an end user ranges from $180.0 Million to $324.0 Million.</p>

Which route of administration is projected to have the same valuation range as the Injectable route?

<p>The Oral route of administration is projected to have the same valuation range as the Injectable route, both between $240.0 Million and $432.0 Million.</p>

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓
%>